

Curriculum Vitae

* Within 2 pages

Name in Full	Chia-Jung Kuo
Country	Taiwan
Affiliation	-Associate Professor, Department of Gastroenterology and Hepatology, Chang Gung Memorial Hospital, Chang Gung University -Secretary General of Taiwan Association for the Study of Small Intestinal Disease (TASSID).
Email	m7011@adm.cgmh.org.tw

Educational Background

Education (Academic Degree) :

-1997-2004 Department of Medicine, College of Medicine, Chang Gung University, Taoyuan, Taiwan

Professional Career

2009/08-present Attending Physician, Department of Gastroenterology and Hepatology, Chang Gung Memorial Hospital, Taiwan

2022/07-present Associate Professor, Department of Gastroenterology and Hepatology, Chang Gung Memorial Hospital, Chang Gung University, Taiwan

2022/03-present Committee member of IBD working group of the Digestive Endoscopy Society of Taiwan (DEST)

2022/03-present Secretary General of Taiwan Association for the Study of Small Intestinal Disease (TASSID)

Research Field

1. Risk of Enteric Infection in Patients with Gastric Acid Suppressive Drugs: A Population-Based Case-Control Study.

Kuo CJ, Lin CY, Chen CW, Hsu CY, Hsieh SY, Chiu CT, Lin WR*.


Journal of Personalized Medicine. 2021 Oct 22;11(11):1063.

2. Clinical Manifestations, Risk Factors, and Prognostic Factors of Cytomegalovirus Enteritis
Yeh PJ, Chiu CT, Lai MW, Wu RC, Chen CM, **Kuo CJ**, Hsu J T, Su MY, Lin WP, Chen TH, Le PH*.
Gut Pathog. 2021 Aug 18;13(1):53.

3. The effectiveness and safety of vedolizumab induction for moderate to severe ulcerative colitis for Asia patient: A real practice observational study.

Kuo CJ, Le PH, Tai WC, Wu KL, Yen HH, Yen CW, Tung SY, Chung CS, Su MY, Chiu CT*.

J Formos Med Assoc. 2021 Dec 16;S0929-6646(21)00532-5



Research Field

4. Colonic Bluish-Black Patches in A 57-Year-Old Woman with Crohn's Disease.
Le PH, **Kuo CJ**, Wu RC. Gastroenterology. 2021 Sep;161(3):e10-e11.
5. Implementation of fecal microbiota transplantation in a medical center for recurrent or refractory *Clostridioides difficile* infection and report of preliminary outcome.
Yeh YM, Cheng HT, Le PH, Chen CC, **Kuo CJ**, Chen CL, Chiu CT, Chiu CH*
Biomed J 2022; 45(3): 504-511
6. Multidrug Resistance: The Clinical Dilemma of Refractory *Helicobacter pylori* Infection.
Kuo CJ, Lee CH, Chang ML, Lin CY, Lin WR, Su MY, Chiu CH, Tseng CN, Wu YS, Chiu CT*, Lai CH*.
J Microbiol Immunol Infect. 2021 Mar 23:S1684-1182(21)00059-1
7. Cytomegalovirus Gastritis: Clinicopathological Profile
Yeh PJ, Chiu CT, Lai MW, Wu RC, **Kuo CJ**, Hsu JT, Su MY, Le PH*
Dig Liver Dis. 2021 Jun;53(6):722-728.
8. Rescue Therapy with Rifabutin Regimen for Refractory *Helicobacter Pylori* Infection with Dual Drug-Resistant Strains.
Kuo CJ, Lin CY, Le PH, Chang PY, Lai CH, Lin WR, Chang ML, Hsu JT, Cheng HT, Tseng CN, Lin CJ, Su MY, Hsieh SY, Chiu CT*
BMC Gastroenterol. 2020 Jul 10;20(1):218.
9. Clinical Characteristics and Outcome of fistulizing Crohn's Disease: One Single Center Experience in Taiwan.
Tony Kuo, **Kuo CJ***, Lin WR, Chiu CT, Su MY, Lin WP, Lin CJ, Hsu JT, Tsai WS, Wu RC.
Adv Dig Med, 2019;6:165-171
10. The Trend of Inflammatory Bowel Diseases in Taiwan: A Population-Based Study.
Kuo CJ, Yu KH, See LC, Chiu CT*, Su MY, Hsu CM, Kuo CF, Chiou MJ, Liu JR, Wang HW.
Dig Dis Sci. 2015 Aug; 60(8):2454-62

